The course of acquired von Willebrand syndrome during pregnancy among patients with essential thrombocytosis

  • Amihai Rottenstreich
  • Geffen Kleinstern
  • Hagai Amsalem
  • Yosef Kalish
Article
  • 5 Downloads

Abstract

To investigate the course of acquired type 2A von Willebrand syndrome (AVWS) in relation to patient management and outcomes among pregnant patients with essential thrombocytosis (ET). A review of pregnant women with ET evaluated for AVWS at the beginning of pregnancy and at the third trimester. Eighteen women with 24 pregnancies were included in this study. A history of bleeding was noted in 8 (44%) patients. In 20 (83%) pregnancies AVWS was evident at the initial testing. Following initial testing, antithrombotic therapy was administered in 22 (92%) pregnancies (aspirin, n = 20 and low-molecular-weight heparin, n = 2). In the remaining two pregnancies, VWF:RCo levels were below 30%; thus, aspirin was given only after repeat testing at 14–16 weeks. At third trimester testing, median VWF:RCo levels were significantly higher than at the initial testing (86 vs. 48%, P < 0.001), with no evidence of AVWS in any of the patients. Significant increases were also observed in the VWF:Ag level (127 vs. 84%, P < 0.001), the VWF:RCo/VWF:Ag ratio (0.75 vs. 0.54, P < 0.001) and the FVIII level (103 vs. 68%, P < 0.001); while platelet count (359 vs. 701 × 109/l, P < 0.001) and hemoglobin level (11.6 vs. 13.4 g/dl, P < 0.001) decreased. Neuraxial anesthesia was safely performed in 17 (71%) pregnancies. No significant bleeding events occurred during pregnancy and delivery. AVWS-related abnormalities in women with ET mostly improved during pregnancy, with favorable maternal and fetal outcomes. VWF parameters should be tested at early pregnancy and repeated at the third trimester, to guide pregnancy and delivery management.

Keywords

Myeloproliferative neoplasms Pregnancy Von Willebrand factor Acquired von Willebrand syndrome Bleeding 

Abbreviations

AVWS

Acquired von Willebrand syndrome

ET

Essential thrombocytosis

VWD

Von Willebrand disease

VWF

Von Willebrand factor

Notes

Acknowledgements

We would like to thank Ms. Cindy Cohen for her editorial assistance.

Author contributions

AR and YK drafted the initial manuscript, reviewed and revised the manuscript. GK performed the statistical analyses for this study. HA, treated the patients and reviewed and revised the manuscript. All authors read and approved the final manuscript as submitted.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the local institutional review board of Hadassah Medical Center Helsinki Committee.

Informed consent

Institutional review board approval waiving informed consent was obtained for this retrospective study.

References

  1. 1.
    Lenting PJ, Christophe OD, Denis CV (2015) von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood 125:2019–2028CrossRefPubMedGoogle Scholar
  2. 2.
    Bremme KA (2003) Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 16:153–168CrossRefPubMedGoogle Scholar
  3. 3.
    Hawke L, Grabell J, Sim W, Thibeault L, Muir E, Hopman W, Smith G, James P (2016) Obstetric bleeding among women with inherited bleeding disorders: a retrospective study. Haemophilia 22:906–911CrossRefPubMedGoogle Scholar
  4. 4.
    Tosetto A, Castaman G (2015) How I treat type 2 variant forms of von Willebrand disease. Blood 125:907–914CrossRefPubMedGoogle Scholar
  5. 5.
    Castaman G (2013) Changes of von Willebrand factor during pregnancy in women with and without von Willebrand disease. Mediterr J Hematol Infect Dis 5:e2013052CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Huq FY, Kadir RA (2011) Management of pregnancy, labour and delivery in women with inherited bleeding disorders. Haemophilia 17:20–30CrossRefPubMedGoogle Scholar
  7. 7.
    Tefferi A (2017) Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 92:94–108CrossRefPubMedGoogle Scholar
  8. 8.
    Rottenstreich A, Kleinstern G, Krichevsky S, Varon D, Lavie D, Kalish Y (2016) Factors related to the development of acquired von Willebrand syndrome in patients with essential thrombocythemia and polycythemia vera. Eur J Intern Med 2016:5466Google Scholar
  9. 9.
    Alimam S, Bewley S, Chappell L, Knight M, Seed P, Gray G, Harrison C, Robinson S (2016) Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol 175:31–36CrossRefPubMedGoogle Scholar
  10. 10.
    Randi ML, Bertozzi I, Rumi E et al (2014) Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol 89:306–309CrossRefPubMedGoogle Scholar
  11. 11.
    Griesshammer M, Struve S, Harrison CM (2006) Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Semin Thromb Hemost 32:422–429CrossRefPubMedGoogle Scholar
  12. 12.
    Tefferi A, Thiele J, Orazi A et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110:1092–1097CrossRefPubMedGoogle Scholar
  13. 13.
    Federici AB, Rand JH, Bucciarelli P et al (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345–349PubMedGoogle Scholar
  14. 14.
    Tiede A, Priesack J, Werwitzke S et al (2008) Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost 6:569–576CrossRefPubMedGoogle Scholar
  15. 15.
    de Maistre E, Volot F, Mourey G et al (2014) Performance of two new automated assays for measuring von Willebrand activity:HemosIL AcuStar and innovance. Thromb Haemost 112:825–830CrossRefPubMedGoogle Scholar
  16. 16.
    Costa-Pinto J, Perez-Rodriguez A, Gomez-del-Castillo MD et al (2014) Diagnosis of inherited von Willebrand disease: comparison of two methodologies and analysis of the discrepancies. Haemophilia 20:559–567CrossRefPubMedGoogle Scholar
  17. 17.
    Rumi E, Pietra D, Ferretti V et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544–1551CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Lee CA, Chi C, Pavord SR, UK Haemophilia Centre Doctors’ Organization et al. (2006) The obstetric and gynaecological management of women with inherited bleeding disorders—review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 12(4):301–336CrossRefPubMedGoogle Scholar
  19. 19.
    Rumi E, Cazzola M (2016) How I treat essential thrombocythemia. Blood 128:2403–2414CrossRefPubMedGoogle Scholar
  20. 20.
    Griesshammer M, Grunewald M, Michiels JJ (2003) Acquired thrombophilia in pregnancy: essential thrombocythemia. Semin Thromb Hemost 29(2):205–212CrossRefPubMedGoogle Scholar
  21. 21.
    Gernsheimer T, James AH, Stasi R (2013) How I treat thrombocytopenia in pregnancy. Blood 121(1):38–47CrossRefPubMedGoogle Scholar
  22. 22.
    Beer PA, Erber WN, Campbell PJ, Green AR (2011) How I treat essential thrombocythemia. Blood 117(5):1472–1482CrossRefPubMedGoogle Scholar
  23. 23.
    Pacheco LD, Costantine MM, Saade GR, Mucowski S, Hankins GD, Sciscione AC (2010) von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. Am J Obstet Gynecol 203:194–200CrossRefPubMedGoogle Scholar
  24. 24.
    Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM (1986) Pregnancy in women with different types of von Willebrand disease. Obstet Gynecol 68(2):282–285PubMedGoogle Scholar
  25. 25.
    Nichols WL, Hultin MB, James AH et al (2008) von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 14(2):171–232CrossRefPubMedGoogle Scholar
  26. 26.
    Trigg DE, Stergiotou I, Peitsidis P, Kadir RA (2012) A systematic review: the use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 18:25–33CrossRefPubMedGoogle Scholar
  27. 27.
    Lancellotti S, Dragani A, Tartaglione R (2015) Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count. J Thromb Haemost 13:1226–1237CrossRefPubMedGoogle Scholar
  28. 28.
    Burke N, Flood K, Murray A, Cotter B, Dempsey M, Fay L et al (2013) Platelet reactivity changes significantly throughout all trimesters of pregnancy compared with the nonpregnant state: a prospective study. BJOG 120:1599–1604CrossRefPubMedGoogle Scholar
  29. 29.
    Reynen E, James P (2016) Von willebrand disease and pregnancy: a review of evidence and expert opinion. Semin Thromb Hemost 42(7):717–723CrossRefPubMedGoogle Scholar
  30. 30.
    Komada T, Kawasaki T, Sata T (2013) Anesthetic management of emergency cesarean section in a patient with acquired vonWillebrand syndrome. Masui 62(11):1368–1371PubMedGoogle Scholar
  31. 31.
    Lipkind HS, Kurtis JD, Powrie R, Carpenter MW (2005) Acquired von Willebrand disease: management of labor and delivery with intravenous dexamethasone, continuous factor concentrate, and immunoglobulin infusion. Am J Obstet Gynecol 192:2067–2070CrossRefPubMedGoogle Scholar
  32. 32.
    Nageswara Rao AA, Rodriguez V, Long ME, Winters JL, Nichols WL, Pruthi RK (2009) Transient neonatal acquired von Willebrand syndrome due to transplacental transfer of maternal monoclonal antibodies. Pediatr Blood Cancer 53:655–657CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Obstetrics and GynecologyHadassah-Hebrew University Medical CenterJerusalemIsrael
  2. 2.Braun School of Public Health and Community MedicineFaculty of Medicine of the Hebrew University and HadassahJerusalemIsrael
  3. 3.Department of Health Sciences ResearchMayo ClinicRochesterUSA
  4. 4.Department of HematologyHadassah-Hebrew University Medical CenterJerusalemIsrael

Personalised recommendations